Sanofi and Owkin Expand AI Partnership With Five-Year Agent Development Deal
Sanofi will deploy Owkin's K Pro AI platform to automate drug discovery and development workflows under a five-year licensing agreement announced this week. Owkin will build custom AI agents designed to function as autonomous assistants performing complex tasks across the pharmaceutical company's research pipeline, from early discovery through clinical trials.
K Pro combines patient data with specialized biological AI systems to support decisions across drug development. The platform launched in 2025 as an agentic AI co-pilot for biomedical research and development.
Thomas Clozel, CEO and cofounder of Owkin, said the deal represents "a shift toward truly embedded AI." The agents will integrate directly into Sanofi's existing workflows, allowing researchers to interact through natural language and access multimodal biomedical data.
Building on Five Years of Collaboration
The companies have worked together since 2021, when Sanofi invested $180 million in Owkin and launched a strategic oncology collaboration. That initial partnership focused on using AI and federated learning for disease modeling, clinical trial design and biomarker detection while preserving data privacy across hospital and research institution datasets.
Sanofi later expanded the relationship into immunology, using AI to support drug positioning and match patient subgroups with specific therapies in its pipeline.
Broader Industry Shift Toward Agentic AI
Life sciences companies are moving beyond isolated analytics tools to embed AI systems into enterprise workflows. Sanofi describes itself as an "R&D-driven, AI-powered biopharma company" and aims to shorten the timeline from discovery to therapy.
Emmanuel Frenehard, Sanofi's chief digital officer, said the company is "continuously investing in frontier AI solutions" to accelerate decision-making throughout drug development. By embedding purpose-built agentic systems into workflows, Sanofi aims to help teams "operate with greater speed, depth, and confidence."
Sanofi has pursued multiple AI partnerships in recent years. In 2024, the company announced a collaboration with Formation Bio and OpenAI to develop AI-powered software that merges data, software and tuned models for custom tools across the drug development lifecycle.
Regulatory Scrutiny Increases
The FDA's Center for Drug Evaluation and Research reported a significant increase in drug applications using AI components, spanning nonclinical, clinical, postmarketing and manufacturing phases. In 2025, the agency issued draft guidance on using AI to support regulatory decision-making for drugs and biological products.
The Sanofi agreement follows another recent K Pro deal. In May, Owkin announced a multi-year license agreement with AstraZeneca to build biopharma agents for competitive intelligence and decision workflows.
For IT and development professionals, understanding generative AI and LLM capabilities is increasingly relevant as pharmaceutical companies deploy these systems. The focus on AI agents and automation in drug development reflects broader enterprise adoption of autonomous AI systems across regulated industries.
Your membership also unlocks:
